Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Revance Therapeutics, Inc. to Host Earnings Call

Accesswire February 28, 2018

Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018

Business Wire February 22, 2018

Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference

Business Wire February 14, 2018

Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018

Business Wire February 1, 2018

Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis

Business Wire January 8, 2018

Revance Provides Update on Anticipated Clinical Milestones and Financial Outlook for 2018

Business Wire January 4, 2018

Report: Exploring Fundamental Drivers Behind Blackhawk Network, TrueCar, Home BancShares, Revance Therapeutics, Heritage Financial, and GMS — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire January 3, 2018

Revance Announces Closing of Public Offering of Common Stock

Business Wire December 11, 2017

Revance Announces Pricing of Public Offering of Common Stock

Business Wire December 7, 2017

Revance Announces Proposed Public Offering of Common Stock

Business Wire December 5, 2017

Mid-Afternoon Market Update: Francesca's Drops On Earnings Miss; Revance Therapeutics Shares Gain

Benzinga.com  December 5, 2017

Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide

Benzinga.com  December 5, 2017

Revance’s RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines

Business Wire December 5, 2017

Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia

Business Wire November 29, 2017

Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia

Business Wire November 20, 2017

Revance Releases Third Quarter 2017 Results

Business Wire November 2, 2017

Revance Therapeutics, Inc. to Host Earnings Call

Accesswire November 2, 2017

Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017

Business Wire October 18, 2017

Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis

Business Wire October 18, 2017

Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

Business Wire September 19, 2017